REGENERON PHARMACEUTICALS, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
REGENERON PHARMACEUTICALS, INC. (REGN) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $7.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Equity
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $7.70M, a 42.59% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $29.10M, a 561.36% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $3.00M, a 97.50% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $5.40M, a 98.27% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $576.20M, a 43.58% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $1.02B, a 44.17% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $708.40M, a 58.94% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $445.70M, a 52.82% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $7.70M 10-Q · filed 2026-07-30 | $36.80M derived: sum of 2 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $29.10M 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | $576.20M 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $3.00M 10-Q · filed 2025-10-28 | $8.40M derived: sum of 2 quarters · filed 2026-07-30 | $12.80M derived: sum of 3 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $5.40M 10-Q · filed 2026-07-30 | $9.80M derived: sum of 2 quarters · filed 2026-07-30 | |||
| 2025-03-31 | $4.40M 10-Q · filed 2026-07-30 | ||||
| 2024-12-31 | $1.02B 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $120.20M 10-Q · filed 2025-10-28 | $432.00M derived: sum of 2 quarters · filed 2025-10-28 | $767.90M derived: sum of 3 quarters · filed 2025-10-28 | ||
| 2024-06-30 | $311.80M 10-Q · filed 2025-10-28 | $647.70M derived: sum of 2 quarters · filed 2025-10-28 | |||
| 2024-03-31 | $335.90M 10-Q · filed 2025-10-28 | ||||
| 2023-12-31 | $708.40M 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $129.40M 10-Q · filed 2024-10-31 | $143.40M derived: sum of 2 quarters · filed 2024-10-31 | $242.60M derived: sum of 3 quarters · filed 2024-10-31 | ||
| 2023-06-30 | $14.00M 10-Q · filed 2024-10-31 | $113.20M derived: sum of 2 quarters · filed 2024-10-31 | |||
| 2023-03-31 | $99.20M 10-Q · filed 2024-10-31 | ||||
| 2022-12-31 | $445.70M 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $108.90M 10-Q · filed 2023-11-02 | $150.80M derived: sum of 2 quarters · filed 2023-11-02 | $256.60M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $41.90M 10-Q · filed 2023-11-02 | $147.70M derived: sum of 2 quarters · filed 2023-11-02 | |||
| 2022-03-31 | $105.80M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $944.60M 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $269.60M 10-Q · filed 2022-11-03 | $295.70M derived: sum of 2 quarters · filed 2022-11-03 | $362.10M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $26.10M 10-Q · filed 2022-11-03 | $92.50M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $66.40M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $768.90M 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $80.90M 10-Q · filed 2021-11-04 | $497.40M derived: sum of 2 quarters · filed 2021-11-04 | $652.50M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $416.50M 10-Q · filed 2021-11-04 | $571.60M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $155.10M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $188.00M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $100.00K 10-Q · filed 2020-11-05 | $29.80M derived: sum of 2 quarters · filed 2020-11-05 | $40.50M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $29.70M 10-Q · filed 2020-11-05 | $40.40M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $10.70M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $187.20M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $45.20M 10-Q · filed 2019-11-05 | $77.10M derived: sum of 2 quarters · filed 2019-11-05 | |||
| 2018-06-30 | $31.90M 10-Q · filed 2019-11-05 | ||||
| 2017-12-31 | $301.70M 10-K · filed 2020-02-07 | $201.62M 10-K · filed 2018-02-08 | |||
| 2016-12-31 | $143.20M 10-K · filed 2019-02-07 | $143.18M 10-K · filed 2017-02-09 | |||
| 2015-12-31 | $160.54M 10-K · filed 2018-02-08 | ||||
| 2014-12-31 | $91.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $202.59M derived: sum of 2 quarters · filed 2017-02-09 | $204.50M derived: sum of 3 quarters · filed 2017-02-09 | $267.58M 10-K · filed 2017-02-09 | |
| 2014-09-30 | $110.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $112.78M derived: sum of 2 quarters · filed 2014-11-04 | $175.87M 10-Q · filed 2014-11-04 | $204.59M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $64.99M 10-Q · filed 2014-08-05 | $93.72M derived: sum of 3 quarters · filed 2016-02-11 | $186.94M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-03-31 | $63.09M 10-Q · filed 2014-05-08 | $91.81M derived: sum of 2 quarters · filed 2016-02-11 | $185.04M derived: sum of 3 quarters · filed 2016-02-11 | $255.09M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2013-12-31 | $28.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $121.95M derived: sum of 2 quarters · filed 2016-02-11 | $192.00M derived: sum of 3 quarters · filed 2016-02-11 | $195.09M 10-K · filed 2016-02-11 | $179.42M 10-K · filed 2014-02-13 |
| 2013-09-30 | $93.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $163.27M derived: sum of 2 quarters · filed 2014-11-04 | $166.36M 10-Q · filed 2014-11-04 | $207.72M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2013-06-30 | $70.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $73.14M 10-Q · filed 2014-08-05 | $114.50M derived: sum of 3 quarters · filed 2015-02-12 | $124.53M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2013-03-31 | $3.08M 10-Q · filed 2014-05-08 | $44.44M derived: sum of 2 quarters · filed 2015-02-12 | $54.48M derived: sum of 3 quarters · filed 2015-02-12 | $66.84M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2012-12-31 | $41.36M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $51.39M derived: sum of 2 quarters · filed 2015-02-12 | $63.76M derived: sum of 3 quarters · filed 2015-02-12 | $112.83M 10-K · filed 2015-02-12 | |
| 2012-09-30 | $10.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $22.40M derived: sum of 2 quarters · filed 2013-11-05 | $71.47M 10-Q · filed 2013-11-05 | $77.60M derived: sum of 4 quarters · filed 2014-02-13 | |
| 2012-06-30 | $12.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $61.44M 10-Q · filed 2013-08-06 | $67.57M derived: sum of 3 quarters · filed 2014-02-13 | $79.17M derived: sum of 4 quarters · filed 2014-02-13 | |
| 2012-03-31 | $49.08M 10-Q · filed 2013-05-03 | $55.20M derived: sum of 2 quarters · filed 2014-02-13 | $66.81M derived: sum of 3 quarters · filed 2014-02-13 | ||
| 2011-12-31 | $6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $17.73M derived: sum of 2 quarters · filed 2014-02-13 | $22.44M 10-K · filed 2014-02-13 | $2.64M 10-K · filed 2012-02-21 | |
| 2011-09-30 | $11.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $16.32M 10-Q · filed 2012-10-24 | |||
| 2011-06-30 | $4.71M 10-Q · filed 2012-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |